News
Projects
Orgs
Project
Articles 71
Votes 0
FiercePharma

Authors 7

FiercePharma
Zoey Becker
Kevin Dunleavy
Max Bayer
Angus Liu
Nick Paul Taylor
Fraiser Kansteiner
Girding against Keytruda cliff, Merck splits oncology into standalone business unit - Fierce Pharma
~1mo
Sanofi ousts Paul Hudson for Merck KGaA chief after 'bumpy ride' - Fierce Pharma
~1mo
FDA tells Sanofi, GSK, AZ and CSL to include warnings for febrile seizures on flu shot labels - Fierce Pharma
2mo
J&J strikes MFN deal with Trump, reveals plan to build 2 US manufacturing sites - Fierce Pharma
3mo
Novo shares tumble after 2 trial misses for semaglutide in Alzheimer's disease - Fierce Pharma
4mo
Bristol Myers braves failed Reblozyl phase 3, plans FDA talks for potential anemia expansion - Fierce Pharma
8mo
Sage lays off entire staff of 338 amid Supernus acquisition - Fierce Pharma
9mo
With Opella proceeds burning a hole in its pocket, Sanofi snaps up Blueprint for $9.1B - Fierce Pharma
10mo
AstraZeneca's first-in-class FDA approval for Truqap marred by surprise restriction - FiercePharma
>2y
Export of Novo Nordisk's Ozempic could be banned in Germany - FiercePharma
>2y
Massive workforce reductions coming, Bayer CEO says - FiercePharma
>2y
Sanofi CEO Hudson's new 'Play to Win' pivot sends stock plunging - FiercePharma
>2y
Merck's Keytruda wins coveted FDA nod around surgery for early lung cancer—with a surprise - FiercePharma
>2y
Pfizer, playing catch-up with Novartis, bags FDA approval for drug combo in lung cancer - FiercePharma
>2y
Study shows Novo's Ozempic, Wegovy pose risk of stomach problems - FiercePharma
>2y
Eli Lilly slapped with third FDA rejection in 2023, this time for eczema treatment lebrikizumab - FiercePharma
>2y
BMS aims for staggering 25 label expansions in the coming years - FiercePharma
>2y
Johnson & Johnson unleashes power of the ampersand as it follows Sanofi, GSK in major rebrand - FiercePharma
>2y
AbbVie's Skyrizi deals heavy blow to J&J's Stelara in head-to-head Crohn's disease study - FiercePharma
>2y
FTC pauses litigation, mulls settlement as industry rallies around Amgen's $28B Horizon deal - FiercePharma
>2y
Cabometyx study ends early after researchers see 'dramatic' benefits in neuroendocrine tumors, Exelixis says - FiercePharma
>2y
FDA approves Pfizer's Abrysvo for pregnancy to protect babies - FiercePharma
>2y
FDA approves Pfizer's Abrysvo for pregnancy to protect babies - FiercePharma
>2y
MSF calls out GSK's ViiV for nondisclosure clauses in contract - FiercePharma
>2y
GSK says RSV shot Arexvy has arrived at major US pharmacies - FiercePharma
>2y